Delivery Order SPE2DB22D3004-SPE2DB25FSA20
- Not listed
- The Defense Logistics Agency (DLA) awarded a $16,914.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens (2 ml unit). The contract was competitively awarded without set-aside designation and carries an ultimate completion date of June 2, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and...
- The Defense Logistics Agency awarded a $109,981.33 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Dupixent 300 mg/2 mL pens. This firm fixed-price contract, with an ultimate completion date of September 16, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The award was competitively awarded with no set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $21,536.39 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on April 24, 2025, with an ultimate completion date of April 25, 2025. The contract employs firm fixed price pricing and was competitively awarded without a set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency awarded a $48,351.90 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 30, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $3,480.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on August 12, 2025, with an ultimate completion date of August 13, 2025. This non-competitive delivery order represents a single pharmaceutical product shipment to support federal medical procurement needs. The awardee, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and veteran...
- The Defense Logistics Agency awarded a $102,906.13 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Dupixent 300 mg/2 mL pens. This is a non-set-aside, competitively awarded contract with a completion date of August 6, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills...
- The Defense Logistics Agency awarded a $10,809.15 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The contract carries no set-aside designation and will be...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $5,128.38 for Dupixent 300 mg/2 ml pen injectors on July 30, 2025, with completion scheduled for July 31, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency has awarded a delivery order valued at $6,837.84 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens. The award, issued on July 30, 2025, represents a firm fixed price delivery order with an ultimate completion date of July 31, 2025, and carries no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $17,370.55 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on September 18, 2025, with an ultimate completion date of September 19, 2025. This is a firm fixed-price, non-set-aside contract executed under an Indefinite Delivery Contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSA20Delivery Order
The Defense Logistics Agency awarded a $10,317.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a non-set-aside contract, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran healthcare systems through the DLA's Medical Supply Chain. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. Dupixent (dupilumab) is a biologic medication used to treat various allergic and inflammatory conditions, including moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. This delivery order fulfills ongoing pharmaceutical supply requirements for military healthcare programs, demonstrating AmerisourceBergen's continued role as a prime vendor supporting the Defense Health Agency and other federal healthcare systems. AmerisourceBergen's comprehensive federal contract portfolio reflects its extensive capabilities in pharmaceutical distribution and its ability to meet complex federal medical supply needs across multiple therapeutic domains through competitively awarded contracts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 8/15/25 |